| Literature DB >> 27548137 |
Chenze Zhang1, Rui Zhao2, Wenqiang Yan3, Hui Wang4, Menglu Jia5, Nailiang Zhu6, Yindi Zhu7, Yuzhong Zhang8, Penglong Wang9, Haimin Lei10.
Abstract
Compounds in the form of precipitation (CFP) are universally formed during the decocting of Chinese prescriptions, such as Huang-Entities:
Keywords: Huang-Lian-Jie-Du-Tang; baicalin–berberine complex; compounds in the form of precipitation; formation mechanism; material foundation; neuroprotective effect
Mesh:
Substances:
Year: 2016 PMID: 27548137 PMCID: PMC6272921 DOI: 10.3390/molecules21081094
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Preparation process of HLJDT CFP.
The HLJDT CFP formation rate from three different batches.
| Batch | Coptidis Rhizoma | Scutellariae Radix | Phellodendri Cortex | Gardeniae Fructus | Total Weight | Precipitation Weight | Precipitation Rate |
|---|---|---|---|---|---|---|---|
| 1 | 9.02 g | 6.00 g | 6.01 g | 9.02 g | 30.05 g | 0.73 g | 2.44% |
| 2 | 9.01 g | 5.99 g | 6.01 g | 9.01 g | 30.02 g | 0.85 g | 2.84% |
| 3 | 9.00 g | 6.00 g | 5.99 g | 9.00 g | 29.99 g | 0.78 g | 2.61% |
| average | 30.02 ± 0.03 g | 0.79 ± 0.06 g | 2.63% ± 0.20% | ||||
Figure 2The chromatogram of HLJDT CFP. The numbers 1–8 represent eight major chemical constituents.
ESI-MSn ions of the identified compounds.
| Peak | Compounds | MS ( | MSn ( | |
|---|---|---|---|---|
| 1 | Geniposide | 21.36 | 386.9 [M − H]− | 224.8 [M − H − C6H10O5]− |
| 2 | Coptisine | 24.15 | 320.0 [M]+ | 292.0 [M − C2H4]+ |
| 3 | Epiberberine | 24.86 | 336.1 [M]+ | 320.1 [M − CH4]+ |
| 4 | Berberine | 28.17 | 336.1 [M]+ | 320.1 [M − CH4]+ |
| 5 | Palmatine | 29.60 | 352.1 [M]+ | 336.1 [M − CH4]+ |
| 6 | Baicalin | 41.76 | 447.1 [M + H]+ | 271.0 [M + H − glua 1]+ |
| 7 | Oroxylin A A-7- | 44.46 | 458.9 [M − H]− | 282.8 [M − H − glua]− |
| 8 | Wogonoside | 45.10 | 458.9 [M − H]− | 282.8 [M − H − glua]− |
1 glua: gluconic acid.
Figure 3The baicalin–berberine complex in methanol solution.
Figure 4The superimposed UV absorption spectroscopy of baicalin, berberine, and baicalin–berberine complex.
Figure 5The 1H-NMR, 13C-NMR of the baicalin–berberine complex. (a) 1H-NMR of the baicalin–berberine complex; and (b) 13C-NMR of the baicalin–berberine complex.
The 1H-NMR, 13C-NMR chemical shift change of the baicalin–berberine complex, contrasted with baicalin.
| Baicalin (δ ppm) | Baicalin–Berberine Complex (δ ppm) | Difference (ppm) |
|---|---|---|
| 2’’, 3’’, 4’’-OH, 5.52–5.31 | 5.04–4.92 | 0.39–0.48 |
| 1’’-H, 5.26 | 4.96 | 0.30 |
| 5’’-H, 4.08 | 3.58 | 0.50 |
| 2’’, 3’’, 4’’-H, 3.47–3.42 | 3.32–3.29 | 0.13–0.15 |
| 6”-C, 170.1 | 171.3 | 1.2 |
| 1”-C, 99.9 | 100.6 | 0.7 |
| 5”-C, 75.5 | 76.0 | 0.5 |
| 3”-C, 75.2 | 73.8 | 1.4 |
| 4”-C, 71.3 | 72.2 | 0.9 |
Figure 6The HR-MS of the baicalin–berberine complex.
The protective effect of HLJDT CFP, baicalin–berberine complex, and baicalin–berberine 1:1 mixture on injured PC12 cells. Data are expressed as means ± SD from three separate experiments.
| Samples | Proliferation Rate (%) | EC50 (μg/mL) | ||||
|---|---|---|---|---|---|---|
| 60 μg/mL | 30 μg/mL | 15 μg/mL | 7.5 μg/mL | 3.75 μg/mL | ||
| HLJDT CFP | 85.08 ± 9.72 | 86.98 ± 10.03 | 96.79 ± 6.52 | 91.53 ± 7.58 | 85.58 ± 9.03 | 3.35 ± 1.11 |
| Baicalin–Berberine complex | 73.62 ± 7.96 | 74.17 ± 7.46 | 81.48 ± 6.08 | 75.10 ± 6.94 | 70.05 ± 8.72 | 5.79 ± 1.67 |
| Baicalin–Berberine 1:1 mixture | 70.45 ± 5.36 | 65.83 ± 5.85 | 59.43 ± 4.43 | 49.38 ± 6.57 | 44.57 ± 6.84 | 11.1 ± 2.49 |
Figure 7The neuroprotective effect tendency of HLJDT CFP, baicalin–berberine complex, and baicalin–berberine 1:1 mixture. Data are expressed as means ± SD from three separate experiments.
Figure 8Morphological changes of PC12 cells assessed by Giemsa staining. (a) Control group; (b) injured by CoCl2; (c) treated with 15 µg/mL HLJDT CFP then injured by CoCl2; and (d) treated with 15 µg/mL baicalin–berberine complex then injured by CoCl2 (×400).
Figure 9The neuroprotective effect of the HLJDT CFP and baicalin–berberine complex assessed by AO/EB staining. (a) Control group; (b) injured by CoCl2; (c) treated with 15 µg/mL HLJDT CFP then injured by CoCl2; and (d) treated with 15 µg/mL baicalin–berberine complex then injured by CoCl2 (×200).
Figure 10The 1H-NMR, 13C-NMR and structure of baicalin and berberine. (a) Structure of baicalin; (b) 1H-NMR of baicalin; (c) 13C-NMR of baicalin; (d) structure of berberine; (e) 1H-NMR of berberine; and (f) 13C-NMR of berberine.